menu
    • menu
    [{"orgOrder":0,"company":"Gate Bioscience","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Gate Bioscience","amount2":0.059999999999999998,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0.059999999999999998,"dosageForm":"Pill","sponsorNew":"Gate Bioscience \/ Versant Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Gate Bioscience \/ Versant Ventures"},{"orgOrder":0,"company":"Gate Bioscience","sponsor":"Forbion | Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Gate Bioscience","amount2":0.070000000000000007,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0.070000000000000007,"dosageForm":"Pill","sponsorNew":"Gate Bioscience \/ Forbion | Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Gate Bioscience \/ Forbion | Eli Lilly"}]

    Find Clinical Drug Pipeline Developments & Deals by Gate Bioscience

    Menu

    Gate Bioscience

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Gate Bioscience

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            Gate Bioscience

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Study Phase : Discovery Platform

                            Sponsor : Forbion | Eli Lilly

                            Deal Size : $65.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Gate Bioscience Raises $65M for Oral Molecular Gate Medicines Clinical Advancement

                            Details : The Series B financing will support the development of an undisclosed product in the miscellaneous category for inflammatory diseases.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            November 13, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Highest Development Status : Discovery Platform

                            Sponsor : Forbion | Eli Lilly

                            Deal Size : $65.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Gate Bioscience

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            Gate Bioscience

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Study Phase : Discovery Platform

                            Sponsor : Versant Ventures

                            Deal Size : $60.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Gate Bioscience Emerges from Stealth and Introduces Molecular Gates, a New Class of Small Molecule Therapeutic...

                            Details : The proceeds will be used for creating a new class of medicines called molecular gates, which are small molecules and eliminate disease-causing extracellular proteins, drivers of diseases, ranging from inflammatory conditions to neurodegenerative disease...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            November 01, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Highest Development Status : Discovery Platform

                            Sponsor : Versant Ventures

                            Deal Size : $60.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth